Albireo Net Cash Flow from Operations from 2010 to 2023

Delisted . USA . 
Stock . Albireo Pharma
ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma Net Cash Flow from Operations yearly trend continues to be very stable with very little volatility. Net Cash Flow from Operations is likely to drop to -99,350,550. During the period from 2010 to 2023, Albireo Pharma Net Cash Flow from Operations quarterly data regression pattern had range of 102,811,000 and median of (18,723,000). Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 26th of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).
  
Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 48.7 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0502, PPandE Turnover of 67.56 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement various Albireo Pharma Technical models . Check out Trending Equities.

Albireo Net Cash Flow from Operations Breakdown

Showing smoothed Net Cash Flow from Operations of Albireo Pharma with missing and latest data points interpolated. A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.Albireo Pharma's Net Cash Flow from Operations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Albireo Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (107.56 M)10 Years Trend
Down
Slightly volatile
Compare to OthersAll Fundamentals
   Net Cash Flow from Operations   
       Timeline  

Albireo Net Cash Flow from Operations Regression Statistics

Arithmetic Mean(42,927,189)
Geometric Mean26,363,886
Coefficient Of Variation(93.34)
Mean Deviation34,717,815
Median(18,723,000)
Standard Deviation40,069,243
Range102,811,000
R-Value(0.84)
R-Squared0.70
Significance0.00017307
Slope(8,040,968)

Albireo Net Cash Flow from Operations History

2023-99.4 M
2022-96.8 M
2021-107.6 M
2020-101 M
2019-52.9 M
2018-26.8 M
2017-27.6 M
2016-8.8 M
2014-4.7 M
2013-18.7 M
2012-18.6 M

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's Net Cash Flow from Operations, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2023
Net Cash Flow from Operations-96.8 M-99.4 M
Free Cash Flow-97.2 M-99.8 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.83ABIOARCA Biopharma Fiscal Quarter End 31st of March 2023 PairCorr
-0.73ABCMAbcamPLCPairCorr
-0.7ABTIAlterola BiotechPairCorr
-0.68ACERAcer Therapeutics Financial Report 15th of May 2023 PairCorr
-0.65AADIAadi Bioscience Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Directory
Find actively traded corporate debentures issued by US companies
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY